ZTOX

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility

Zydus Lifesciences (ZYDUSLIFE): Buyback

Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback

Zydus Lifesciences Announces Share Buyback via NSE Filing

Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has notified the exchanges about a share buyback program. The announcement signals the pharma major's intent to return capital to shareholders.

Zydus Lifesciences (ZYDUSLIFE): Buyback

Zydus Lifesciences (ZYDUSLIFE): Company Update

Company Update Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.

Zydus Lifesciences (ZYDUSLIFE): Press Release

Press Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority

Jun 3, 2026 1 min read

Zydus Lifesciences Subsidiary Gets CGST Demand Order from Ahmedabad Authority

Zydus VTEC Limited, the wholly owned subsidiary of Zydus Lifesciences, has received a Demand Order-In-Original from the Deputy Commissioner of CGST & Central Excise based in Ahmedabad North Commissionerate.